Risk Management Plan

for ZILBRYSQ^® (zilucoplan)

Public Mobile Menu

Website Terms and Conditions of Use
Privacy Policy
Cookie policy

Back to top

This site is intended for Healthcare Professionals only.

https://www.ucb.com/UCBCares

ZILBRYSQ is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti‑acetylcholine receptor (AChR) antibody positive.

Produced by

Date of preparation: February 2024

EU-ZL-2300021

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions. Healthcare Professionals should report suspected adverse reactions via their national reporting system.

Terms and Conditions of Use
Privacy Policy
Cookie Policy
Cookie Preferences